It was a pleasure to talk to Pat Penovich (Minnesota Epilepsy Group, St. Paul, MN, USA) about the exit survey, of a Phase 3 study, assessing patient experience of using the diazepam nasal spray for seizure clusters. The abstract ‘Examining the Patient Experience With Diazepam Nasal Spray for Seizure Clusters: Patient-reported Results From an Exit Survey of a Phase 3, Open-label, Repeat Dose Safety Study.’ was presented at the virtual AES 2020, 4-8 December 2020.
Questions
- What are the advantages of intranasal delivery of rescue medications compared with current options in patients with epilepsy clusters? (0:05)
- Could you tell us a little about the diazepam nasal spray and it’s indications? (1:36)
- Could you give us an overview of your recent study on patient experience with diazepam nasal spray? (2:44)
- What were the findings of the study and what are the implications for future clinical practice? (3:50)
- Which patients are most likely to benefit from the diazepam nasal spray? (5:12)
Disclosures: Consultant and on Speaker’s Bureau for Neurelis, SK and UCB; Speaker’s Bureau for Greenwich; and Consultant for Marinus and LVIS.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AES 2020, 4-8 December, 2020 (Virtual).
